Edwards Lifesciences (EW) Stock Forecast & Price Target

Compare

1,882 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EW Analyst Ratings

Moderate Buy

15 Buy

11 Hold

0 Sell

Based on 26 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

$88.46

▲(8.99%Upside)

Based on 26 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $88.46 with a high forecast of $101.00 and a low forecast of $79.00. The average price target represents a 8.99% change from the last price of $81.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","81":"$81","102":"$102","70.5":"$70.5","91.5":"$91.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":101,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$101.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$79.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,70.5,81,91.5,102],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.18,79.0123076923077,80.8446153846154,82.67692307692309,84.50923076923077,86.34153846153846,88.17384615384616,90.00615384615385,91.83846153846154,93.67076923076922,95.50307692307692,97.33538461538461,99.1676923076923,{"y":101,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.18,78.04769230769232,78.91538461538462,79.78307692307693,80.65076923076923,81.51846153846154,82.38615384615385,83.25384615384615,84.12153846153846,84.98923076923077,85.85692307692307,86.72461538461538,87.59230769230768,{"y":88.46,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.18,77.32000000000001,77.46000000000001,77.60000000000001,77.74000000000001,77.88000000000001,78.02000000000001,78.16,78.3,78.44,78.58,78.72,78.86,{"y":79,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":90.25,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.86,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.96,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.54,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.62,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.18,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$101.00

Average Price Target$88.46

Lowest Price Target$79.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$85

Buy

4.73%

Upside

Reiterated

07/29/25

Edwards Lifesciences' strong financial health and positive earnings call sentiments are the most significant factors driving the stock score. However, high valuation metrics and operational efficiency challenges slightly dampen the outlook. The company's strategic corporate events support a favorable long-term view.

Marie ThibaultBTIG

BTIG

$100

Buy

23.21%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Buy from Neutral at BTIGEdwards Lifesciences upgraded to Buy from Neutral at BTIG

Narumi NakagiriDaiwa

Daiwa

$89

Buy

9.66%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Outperform from Neutral at DaiwaEdwards Lifesciences upgraded to Outperform from Neutral at Daiwa

Mike KratkyLeerink Partners

Leerink Partners

$83→$84

Hold

3.50%

Upside

Reiterated

07/28/25

Edwards Lifesciences (EW) Receives a Hold from Leerink Partners

Lee HambrightBernstein

Bernstein

$80→$85

Hold

4.73%

Upside

Reiterated

07/28/25

Edwards Lifesciences (EW) Receives a Hold from BernsteinBernstein SocGen Group analyst Lee Hambright raised the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $80.00) while maintaining a Market Perform rating.

Unknown AnalystUBS

Not Ranked

UBS

$80→$85

Hold

4.73%

Upside

Reiterated

07/28/25

UBS Sticks to Its Hold Rating for Edwards Lifesciences (EW)

Richard NewitterTruist Financial

Truist Financial

$81→$82

Hold

1.03%

Upside

Reiterated

07/25/25

Truist Financial Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Adam MaederPiper Sandler

Piper Sandler

$83→$90

Buy

10.89%

Upside

Reiterated

07/25/25

Piper Sandler Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Suraj KaliaOppenheimer

Oppenheimer

$90

Buy

10.89%

Upside

Reiterated

07/25/25

Edwards Lifesciences (EW) Gets a Buy from Oppenheimer

Larry BiegelsenWells Fargo

Wells Fargo

$80→$84

Buy

3.50%

Upside

Reiterated

07/25/25

Wells Fargo Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Pito ChickeringDeutsche Bank

Deutsche Bank

$85→$94

Buy

15.82%

Upside

Reiterated

07/25/25

Edwards Lifesciences price target raised to $94 from $85 at Deutsche BankEdwards Lifesciences price target raised to $94 from $85 at Deutsche Bank

Anthony PetroneMizuho Securities

Mizuho Securities

$87→$95

Buy

17.05%

Upside

Reiterated

07/25/25

Edwards Lifesciences (EW) Gets a Buy from Mizuho SecuritiesMizuho analyst Anthony Petrone raised the price target on Edwards Lifesciences (NYSE: EW) to $95.00 (from $87.00) while maintaining a Outperform rating.

David RescottRobert W. Baird

Robert W. Baird

$78→$79

Hold

-2.66%

Downside

Reiterated

07/25/25

Edwards Lifesciences price target raised to $79 from $78 at BairdEdwards Lifesciences price target raised to $79 from $78 at Baird

Josh JenningsTD Cowen

TD Cowen

$75→$84

Hold

3.50%

Upside

Reiterated

07/25/25

Edwards Lifesciences: Strong Performance Yet Limited Upside Justifies Hold Rating

Rick WiseStifel Nicolaus

Stifel Nicolaus

$90→$95

Buy

17.05%

Upside

Reiterated

07/25/25

Stifel Nicolaus Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$85

Buy

4.73%

Upside

Reiterated

07/29/25

Marie ThibaultBTIG

BTIG

$100

Buy

23.21%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Buy from Neutral at BTIGEdwards Lifesciences upgraded to Buy from Neutral at BTIG

Narumi NakagiriDaiwa

Daiwa

$89

Buy

9.66%

Upside

Upgraded

07/29/25

Edwards Lifesciences upgraded to Outperform from Neutral at DaiwaEdwards Lifesciences upgraded to Outperform from Neutral at Daiwa

Mike KratkyLeerink Partners

Leerink Partners

$83→$84

Hold

3.50%

Upside

Reiterated

07/28/25

Edwards Lifesciences (EW) Receives a Hold from Leerink Partners

Lee HambrightBernstein

Bernstein

$80→$85

Hold

4.73%

Upside

Reiterated

07/28/25

Unknown AnalystUBS

Not Ranked

UBS

$80→$85

Hold

4.73%

Upside

Reiterated

07/28/25

UBS Sticks to Its Hold Rating for Edwards Lifesciences (EW)

Richard NewitterTruist Financial

Truist Financial

$81→$82

Hold

1.03%

Upside

Reiterated

07/25/25

Truist Financial Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Adam MaederPiper Sandler

Piper Sandler

$83→$90

Buy

10.89%

Upside

Reiterated

07/25/25

Piper Sandler Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Suraj KaliaOppenheimer

Oppenheimer

$90

Buy

10.89%

Upside

Reiterated

07/25/25

Edwards Lifesciences (EW) Gets a Buy from Oppenheimer

Larry BiegelsenWells Fargo

Wells Fargo

$80→$84

Buy

3.50%

Upside

Reiterated

07/25/25

Wells Fargo Sticks to Their Buy Rating for Edwards Lifesciences (EW)

Pito ChickeringDeutsche Bank

Deutsche Bank

$85→$94

Buy

15.82%

Upside

Reiterated

07/25/25

Edwards Lifesciences price target raised to $94 from $85 at Deutsche BankEdwards Lifesciences price target raised to $94 from $85 at Deutsche Bank

Anthony PetroneMizuho Securities

Mizuho Securities

$87→$95

Buy

17.05%

Upside

Reiterated

07/25/25

David RescottRobert W. Baird

Robert W. Baird

$78→$79

Hold

-2.66%

Downside

Reiterated

07/25/25

Edwards Lifesciences price target raised to $79 from $78 at BairdEdwards Lifesciences price target raised to $79 from $78 at Baird

Josh JenningsTD Cowen

TD Cowen

$75→$84

Hold

3.50%

Upside

Reiterated

07/25/25

Edwards Lifesciences: Strong Performance Yet Limited Upside Justifies Hold Rating

Rick WiseStifel Nicolaus

Stifel Nicolaus

$90→$95

Buy

17.05%

Upside

Reiterated

07/25/25

Stifel Nicolaus Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

1 Month

xxx

Success Rate

12/17 ratings generated profit

Average Return

+2.92%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +2.92% per trade.

3 Months

xxx

Success Rate

16/22 ratings generated profit

Average Return

+2.50%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +2.50% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

16/22 ratings generated profit

Average Return

+8.51%

reiterated a buy rating 7 days ago

Copying Rick Wise's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +8.51% per trade.

2 Years

xxx

Success Rate

15/22 ratings generated profit

Average Return

+13.95%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.18% of your transactions generating a profit, with an average return of +13.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EW has received 25 Buy Ratings, 21 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 88.46.

Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $0.59 with a range of $0.56 to $0.64. The previous quarter’s EPS was $0.67. EW beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.25% of the time in the same period. In the last calendar year EW has Outperformed its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $1.50B with a range of $1.46B to $1.52B. The previous quarter’s sales results were $1.53B. EW beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.67% of the time in the same period. In the last calendar year EW has Outperformed its overall industry.

EW Stock Forecast FAQ

What is EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is 88.46.

What is EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences has 8.99% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EW a Buy, Sell or Hold?

Edwards Lifesciences has a consensus rating of Moderate Buy which is based on 15 buy ratings, 11 hold ratings and 0 sell ratings.

What is Edwards Lifesciences’s price target?

The average price target for Edwards Lifesciences is 88.46. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $101.00 ,the lowest forecast is $79.00. The average price target represents 8.99% Increase from the current price of $81.16.

What do analysts say about Edwards Lifesciences?

Edwards Lifesciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 26 Wall Streets Analysts.

How can I buy shares of EW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Analyst Recommendation Trends

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts